Business Overview / Sources of Revenue

DexCom is a **medical device company** that designs, manufactures, and sells **continuous glucose monitoring (CGM) systems** used primarily by people with diabetes in the U.S. and internationally.[2][3] Its core products include the **Dexcom G6, G7, Dexcom ONE, Share, Real-Time API, and Stelo** sensors and software ecosystem.[2]

DexCom generates **nearly all of its revenue from sales of CGM systems**, particularly **disposable sensors**, with additional revenue from transmitters and receivers.[1][3] Public filings and analyses indicate **over 90% of revenue comes from sensor sales**, with the remainder largely from hardware (transmitters/receivers) and data/software services; DexCom does **not** meaningfully rely on services or licensing as standalone segments.[1][3]

Revenue is geographically diversified, with the **United States contributing the majority** and the rest from international markets, but the business is fundamentally driven by recurring CGM sensor usage tied to its installed user base.[2][3]

Revenue Growth Potential and Recurrence

DexCom’s revenue is **overwhelmingly recurring**, with **sensors and other recurring items making up about 97% of sales**, versus only ~3% from hardware.[1] This stems from disposable CGM sensors that must be replaced regularly and ongoing subscription-like services.[1][2]

Recent growth has re-accelerated: Q3 2025 revenue rose **22% year over year** (20% organic), following **15%** growth in Q2 2025 and guidance for **14–15%** full‑year 2025 growth.[1][5][6][7] Over the last two years, organic revenue averaged about **17%** annually.[4]

Consensus forecasts call for revenue to grow around **11–12% per year** over the medium term, with earnings growing faster as margins expand.[3] Given large untapped type 2 diabetes and international markets, many analysts see **low‑ to mid‑teens annual revenue growth** as reasonable over the next 5+ years, assuming continued CGM adoption and reimbursement support.[1][3][4][8]

Economic Moat Factors

DexCom has a **moderate but real economic moat**, led by **switching costs**, **brand**, and **regulatory/technical barriers**, but it faces credible competition (Abbott, Medtronic) that limits moat strength.[3][5]

Patients, clinicians, and payors incur hassle and clinical risk in changing CGM systems (new training, prescriptions, insurance approvals, integration with pumps), creating **high switching costs** once a user is embedded in the DexCom ecosystem.[3][5] Its CGMs are widely viewed as a **premium “gold standard”** for accuracy and real‑time data, giving DexCom **brand power** in specialist prescribing and reimbursement decisions.[3][5] Proprietary sensor technology, extensive clinical/health‑economic evidence, and lengthy FDA/international approval cycles form **regulatory and intellectual‑property barriers** that slow new entrants.[3][4][5] However, there are **no strong network effects or clear scale advantages**, and aggressive pricing and ecosystem bundling by Abbott and Medtronic can pressure margins, keeping the moat durable but not impregnable.[1][3][5]

Leadership

Dexcom’s leadership is led by **Kevin Sayer**, a long‑time executive but **not a founder**; the company was founded in 1999 by Scott Glenn and others.[1][3] Sayer has been CEO since **January 2015** and chairman since 2018.[1][2] He is currently on leave while **President/COO Jake Leach** serves as interim CEO and is slated to become permanent CEO on **Jan 1, 2026**.[3][4] Sayer owns roughly **0.06%** and Leach about **0.07–0.08%** of Dexcom shares, with an experienced executive team averaging over four years’ tenure.[3]

Financial Health

Dexcom has a **strong balance sheet**, with cash and short-term investments (~$2.9B) exceeding total debt (~$2.45B), meaning **net cash rather than net debt**.[1] Short‑term assets comfortably cover both short- and long-term liabilities.[1] Operating cash flow covers debt well (debt is 40% of operating cash flow), and the business is solidly profitable, so it **does generate free cash flow**.[1] That implies a healthy positive FCF margin, though exact TTM FCF margin is not disclosed in the cited data. Share count has generally **trended upward** over time (stock‑based compensation, acquisitions), so the company has been **net dilutive, not a consistent repurchaser**.[1][5]

Last updated Dec 6, 2025